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Abstract
Background: Dermatomyositis is an autoimmune myopathy characterized by proximal muscle weakness, muscle
inflammation, and typical skin findings. It is a rare disease with an incidence of ~1/100 000. About 15–30 % of
adult-onset cases are caused by underlying malignancy and dermatomyositis can be the first symptom of
undiagnosed cancer, mainly in the case of anti-transcription intermediary factor 1γ (anti-TIF-1γ) antibodies presence.
TIF-1γ is a transcriptional cofactor which is implicated in TGFβ signaling pathway that controls cell proliferation,
differentiation, apoptosis, and tumorigenesis. Its expression was shown to be associated with younger age, higher
tumor grade, more estrogen receptor negativity, tumors larger than 2 cm, and tendency towards poor outcome in
early breast cancer. No association between anti-TIF-1γ antibodies and prognosis has been proposed yet.
Case presentation: We report a case of a 43-year-old premenopausal woman presenting with the symptoms of
systemic rheumatic disease, the most prominent being a typical skin rash and muscle pain. After a series of
investigations, the patient was diagnosed with anti-TIF-1γ positive dermatomyositis and concurrent triple-negative
breast cancer (cT1c N3c M0) as an underlying cause. Immediate intravenous corticosteroid therapy relieved the
symptoms and enabled anticancer therapy to be commenced. Considering the tumor stage, neoadjuvant therapy
with 4 courses of AC (Doxorubicin/Cyclophosphamide) followed by 4 courses of Paclitaxel/Carboplatin was
administered. However, no tumor regression was documented and radiotherapy was chosen as the definitive
treatment.
Conclusion: Early detection of anti-TIF-1γ autoantibodies can contribute to a rapid diagnosis of tumor-associated
dermatomyositis and enable immediate anticancer treatment. We demonstrate the emerging role of anti-TIF-1γ
antibodies in the diagnostics of tumor-associated dermatomyositis. Furthermore, we propose a potential role of
anti-TIF-1γ antibodies as a prognostic marker in early breast cancer patients.
Keywords: Autoantibodies, Breast cancer, Dermatomyositis, Paraneoplastic, Case report
Abbreviations: AUC, Area under the curve; CEA, Carcinoembryonic antigen; CK, Creatine kinase; CRP, C-reactive
protein; DM, Dermatomyositis; ER, Estrogen receptor; ESR, Erythrocyte sedimentation rate; FDG, Fluorodeoxyglucose;
HER2, Human epidermal growth factor receptor 2; IMCCP, The International Myositis Classification Criteria Project;
ISH, In situ hybridization; pCR, Pathologic complete response; PET/CT, Positron emission tomography-computed
tomography; PgR, Progesteron receptor; TGFβ, Transforming growth factor β; TIF-1γ, Transcription intermediary
factor 1γ
* Correspondence: okubec@gmail.com
1Department of Oncology and Radiotherapy, Charles University in Prague,
Faculty of Medicine and University Hospital in Hradec Králové, Sokolská 581,
500 05 Hradec Králové, Czech Republic
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kubeček et al. BMC Cancer  (2016) 16:684 
DOI 10.1186/s12885-016-2715-1
Background
Dermatomyositis (DM) together with polymyositis and in-
clusion body myositis belong to a group of acquired skeletal
muscle diseases known as idiopathic inflammatory myop-
athies [1]. DM is considered an autoimmune disease. It
may present with variously expressed clinical signs, the
most prominent being characteristic rash and muscle weak-
ness. The skin manifestations include heliotrope rash on
the upper eye lids, erythematous rash localized on the face,
neck, anterior chest, back, and large joints [2]. Gottron rash
refers to violaceous rash or papules localized typically in
metacarpophalangeal, and proximal or distal interphalan-
geal joints. Together with heliotrope rash, it is considered a
specific cutaneous feature of the disease. Proximal muscle
weakness usually develops slowly over weeks or months
[3]. DM is associated with presence of specific autoanti-
bodies which are usually divided into myositis specific auto-
antibodies (including anti-Mi-2, anti-CADM-140, anti-SAE,
anti-p155/140 (anti-TIF-1γ), anti-MJ, anti-t-RNA synthe-
tase, and anti-PMS1 antibodies) and myositis associated
autoantibodies (including anti-Ro/SSA, anti-U1RNP, anti
PM/Scl, and Anti-Ku antibodies) [4]. Recently, a remark-
able association between several antibodies and specific
clinical presentations have been found [5]. The majority of
cases are idiopathic. However, in ~15–30 % of adult-onset
cases, DM is associated with malignancy. Cancer may occur
before, at the same time, or following the diagnosis of DM.
DM that develops as a consequence of the tumor presence
in the body is classified as paraneoplastic. The mechanism
how malignancy induces DM is not clear yet. However, sev-
eral possible mechanisms have been proposed. It has been
demonstrated that some tumors, including breast adeno-
carcinoma, express high levels of myositis autoantigens [6].
These antigens can also be found in regenerating myoblasts
in affected muscles from myositis patients. It is therefore
possible that immune response directed against cancer cells
cross-reacts with regenerating muscle cells and could there-
fore be responsible for the pathogenesis of DM [6]. The
most common tumor types associated with DM include
gynecological tumors (mainly ovarian cancer), lung, pan-
creatic, gastric, colorectal cancer, and non-Hodgkin’s
lymphoma [7]. The most common tumor sites in men are
lung, prostate, and stomach. This contrasts with DM in
women, which is most frequently associated with tumors
of breast, ovary, and uterus [8]. The spectrum of tumor
types varies greatly across different regions. DM in Asian
populations is, for example, more frequently associated
with a nasopharyngeal cancer [9]. The first case of DM as-
sociated with breast cancer was reported in 1916 [10]. Ac-
cording to published population-based studies, breast
cancer is diagnosed in ~10–20 % of malignancy-associated
DM cases [8].
Triple-negative cancer is an intrinsic subtype of breast
cancer. It is defined by the absence of estrogen receptor
(ER), progesterone receptor (PgR), and human epidermal
growth factor receptor 2 (HER2) overexpression and/or
gene amplification [11]. It accounts for 15–20 % of
newly diagnosed breast cancer cases [12]. Typical fea-
tures include younger age at diagnosis, poorer prognosis,
and association with BRCA 1/2 mutations [12]. No data
regarding the incidence of anti-TIF-1γ autoantibodies in
triple-negative breast cancer has been published so far.
Case presentation
A forty-three-year-old premenopausal caucasian woman
with no relevant medical history presented with inter-
mittent fever, fatigue, myalgia, dysphagia, and erythema-
tous rash lasting over 1 month. The nonpruritic macular
rash was initially localized on the back of patient’s hands
and was followed by eruption of erythema over patient’s
face after 1 week. The onset of pruritic macular rash on
lateral sites of patient’s thighs and upper part of back
followed. The patient presented first to her dermatolo-
gist who treated her with topical steroids for 2 weeks.
However, no clinical effect was observed. Considering
the skin manifestation and other symptoms suspicious
of a systemic rheumatic disease, the patient was referred
to a rheumatologist. She was later admitted to a hospital
to establish a diagnosis and commence treatment.
The skin examination revealed a slight periorbital
edema (Heliotrope rash) and erythematous rash local-
ized over her cheeks and nasal bridge omitting the naso-
labial sulcus. It was therefore resembling a typical malar
rash in lupus erythematosus (Fig. 1). Erythematous hy-
perpigmented papules were found over the proximal and
distal interphalangeal joints (Gottron’s sign). The pruritic
maculopapular rash was also present on lateral sites of
patient’s thighs and back (Figs. 2 and 3). V-sign, a typical
distribution of macular exanthema on the front site of
patient’s chest, was found (Fig. 4). The physical examin-
ation also revealed enlarged lymph nodes in her left ax-
illa and supraclavicular region, which was further
confirmed by ultrasound (Fig. 5), and painful swelling
and enlargement of the whole left mammary gland.
Blood investigations revealed raised erythrocyte sedimen-
tation rate (ESR, 34 mm/h). C-reactive protein (CRP) was
slightly elevated (12.4 mg/L). Serum muscle enzyme con-
centrations were also elevated - alanine aminotransferase
(0.71 μkat/L), aspartate aminotransferase (1.38 μkat/L), cre-
atine kinase (CK, 26.24 μkat/L), and myoglobin (267 μg/L).
Electromyography revealed no pathological findings. Skin
biopsy from the affected area was performed with negative
lupus band test (direct immunofluorescence test for lupus
erythematosus). The whole panel of autoantibodies was
examined using immunoblot technique (Euroimmun,
Euroline Autoimmune Inflammatory Myopathies 16 Ag)
with only anti-TIF-1γ antibodies being positive. The prob-
ability of DM was evaluated > 90 % using the IMCCP (The
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International Myositis Classification Criteria Project) cri-
teria [13]. Muscle biopsy is not mandatory in the presence
of typical skin manifestations according to these criteria.
Considering the high probability of DM, further supported
by the presence of anti-TIF-1γ, a muscle biopsy was omit-
ted. Because of the patient’s complains of dysphagia gastro-
duodenoscopy was performed to exclude the upper
Fig. 2 Maculopapular rash on lateral sites of patient’s thighs
Fig. 3 Maculopapular rash on patient’s back
Fig. 4 V-sign (macular exanthema on the front site of
patient’s chest)
Fig. 1 Erythematous rash localized over the cheeks and nasal bridge
omitting the nasolabial sulcus resembling a typical malar rash in
lupus erythematosus
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gastrointestinal tract involvement. The finding was consist-
ent with erosive antral gastritis with negative rapid urease
test (rapid diagnostic test for Helicobacter pylori infection).
Series of investigations were performed to exclude an
extra-muscular involvement - ophthalmologic, otorhinolar-
yngologic, neurologic, cardiac and renal - all with negative
findings. Tumor markers including CEA, CA 15–3, CA
125, and CA 19–9 were negative. Mammography was
performed to exclude breast cancer as an underlying condi-
tion. The result, however, was equivocal (sporadic microcal-
cifications without any obvious tumor mass). Neither
ultrasound of the abdomen nor chest x-ray showed any ab-
normality. Since the conventional investigations were not
conclusive, a whole body PET/CT scan was performed to
exclude malignancy. The scan showed FDG-avid lesion
19 × 14 mm in the left mammary gland, and multiple FDG-
avid lymph nodes in the left axilla and under the pectoralis
major muscle (Figs. 6 and 7).
Direct core cut biopsy was not feasible since there was no
evident mass within the breast according to mammog-
raphy. Extirpation of the left supraclavicular lymph node
was therefore performed to obtain the histopathological
specimen and confirm the diagnosis. Metastasis of poorly
differentiated adenocarcinoma was reported (Fig. 8). Immu-
nohistochemical assessment of steroid hormone status was
performed. The expression of the estrogen and progesteron
receptors, and HER-2/neu protein were all negative. Add-
itional in situ hybridization (ISH) found no HER-2/neu
amplification, thus confirming the diagnosis of the triple-
negative breast cancer. The disease was staged as cT1c N3c
M0. Genetic testing to exclude BRCA 1/2 mutation was ad-
vised, considering the patient’s age and histological type of
breast cancer (triple-negative).
The treatment of DM was initiated with intravenous
pulse corticosteroid therapy (methylprednisolone 5 ×
1000 mg alternate days), followed by oral corticosteroids.
Fig. 5 Ultrasound image of enlarged lymph node in the left axilla
Fig. 6 PET/CT showing FDG-avid lesion 19 × 14 mm in the left
mammary gland
Fig. 7 PET/CT showing multiple FDG-avid lymph nodes in the left
axilla and under the pectoralis major muscle
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Initial daily dose of 32 mg of methylprednisolone was re-
duced by 8 mg every week to the maintenance dose of
8 mg/day. The muscle strength tended to deteriorate dur-
ing the deescalation phase. This prompted the contempor-
ary discontinuation of dose reduction, until muscle
weakness improved (CK 1.03 μkat/L, myoglobin 25.5 μg/L).
The symptoms of dysphagia and skin manifestation were
promptly managed, enabling the anti-cancer therapy to be
commenced. Considering both disease burden and histo-
logic features, neoadjuvant chemotherapy was decided to
be the option. The regimen containing 4 courses of doxo-
rubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 q3w
followed by 4 courses paclitaxel 175 mg/m2 + carboplatin
AUC 5 q3w was chosen. The patient continued with a
maintenance dose of corticosteroids during the chemother-
apy, which was well tolerated. However, the investigations
following the last dose of chemotherapy (mammography,
ultrasound of the breast and regional lymph nodes), did not
show any signs of tumor regression. Surgery was still not
feasible because of the supraclavicular and axillary lymph
node persistence. Radiotherapy was therefore decided to be
the option by the multidisciplinary board (including on-
cologist, breast surgeon and radiologist) in order to achieve
local control. Primary chemoresistance of the tumor was an
additional reason to support this approach.
Discussion
Cancer should always be considered as an underlaying
cause of DM. Several risk factors have been proposed to
be related with increased risk of malignancy in DM pa-
tients. An extensive meta-analysis of clinical trials found
older age, male sex, dysphagia, cutaneous necrosis, cuta-
neous vasculitis, rapid onset (<4 weeks), elevated CK,
higher ESR, and higher CRP as factors to be associated
with higher risk [14]. Considering the high incidence of
cancer in DM patients, it is the author’s opinion that
every patient with DM should be thoroughly investigated
to exclude the malignancy with an extra effort in pa-
tients bearing one or more of above named risk factors.
The diagnosis of DM is traditionally based on five cri-
teria published by Bohan and Peter in 1975: 1) Symmetric
proximal muscle weakness, 2) Muscle biopsy evidence of
myositis, 3) Increase in serum skeletal muscle enzymes, 4)
Characteristic electromyographic patterns, and 5) Typical
rash of dermatomyositis. Two of these criteria were
present together with typical skin manifestation which
made the diagnosis of DM probable in presented case
[15]. However, these criteria seem to be inadequate in sev-
eral aspect (e.g. including patients with some forms of
muscle dystrophy). Novel criteria suitable to be used
within clinical trials have therefore been proposed recently
[13]. Using the IMCCP criteria (The International Myo-
sitis Classification Criteria Project) in our patient, the
probability of DM was evaluated > 90 %.
Anti-TIF-1γ antibodies were positive while anti-NXP-2
(anti-nuclear matrix protein NXP-2) antibodies were
negative in presented patient. It has been shown that the
presence of anti-TIF-1γ and anti-NXP-2 antibodies is
frequent in DM patients [5]. These autoantibodies are
present in most patients with cancer-associated DM
(found in 83 % cases - 31 % anti-NXP-2 and 52 % anti-
TIF-γ), which could make them a useful tool to identify
patients with malignancy alongside the DM [5]. Further-
more, it was observed that these antibodies are almost
exclusively non-overlapping and that the vast majority of
individuals with positivity of either antibody is negative
in other DM-specific or myositis-specific antibodies as
observed in our patient [5]. Thus, the involvement of
these antibodies in the primary diagnostics of DM could
identify patients with otherwise negative autoantibodies.
TIF-1γ is a transcriptional cofactor which is implicated
in TGFβ signaling pathway that controls cell prolifera-
tion, differentiation, apoptosis and tumorigenesis [16].
Results of a study evaluating the role of TIF-1γ and its
interaction with TGFβ1/SMAD4 signaling pathway as a
prognostic factor in operable breast cancer have been
published recently [17]. TIF-1γ expression was shown to
be associated with younger age, higher tumor grade,
more estrogen receptor (ER) negativity, and tumors lar-
ger than 2 cm [17]. Furthermore, TIF1γ expression
showed tendency towards poor outcome. The subgroup
of patients expressing both TGFβ1 and TIF1γ showed
the poorest outcome in the studied population [17]. We
propose that if the correlation of serum anti-TIF-1γ anti-
bodies and TIF-1γ expression in the tumor was found,
the anti-TIF-1γ antibodies might serve as a potential
prognostic marker in early breast cancer patients.
DM is considered a potentially treatable disease. Sys-
temic corticosteroids remain a mainstay in therapy. Oral
Fig. 8 Light microscope image of lymph node infiltrated with
metastasis of poorly differentiated adenocarcinoma (Haematoxylin
and Eosin stain)
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prednisone at initial dose of 0.5–1 mg/kg/day should be
given as initial therapy, followed by a slow progressive
dose reduction not earlier than 6 weeks after the myo-
sitis has become inactive (clinically and enzymatically)
[18]. In severe cases, intravenous methylprednisolone is
the treatment option [19]. Some patients, however, do
not respond to corticosteroids or develop serious side ef-
fects. In such cases, introduction of immunosuppressive
agents is recommended. The most widely used drugs in-
clude methotrexate, azathioprine, cyclophosphamide or
cyclosporin A [3]. The surgical removal of the tumor or
anti-cancer treatment may itself result in disappearance
or reduction of the paraneoplastic symptoms [20]. Meth-
ylprednisolone pulse therapy seems to relieve dysphagia
in DM patients [21]. This finding together with urgency
to achieve a rapid response was the reason to choose the
initial pulse corticotherapy. The symptoms of the disease
were managed soon after making the diagnosis and the
patient was ready to begin the anti-cancer treatment
without undue delay.
Conclusions
DM can be the first symptom of previously undiagnosed
malignancy. When confirming the diagnosis of DM, ma-
lignancy should always be excluded. The anti-TIF-1γ
and anti-NXP-2 antibodies may play an essential role in
rapid diagnosis of malignancy associated DM, especially
in patients bearing several risk factors known to be asso-
ciated with malignancy. Considering the fact that indi-
viduals with positivity of either of these antibodies are
very frequently negative in other DM-specific and
myositis-specific antibodies, their assessment within pri-
mary diagnostics might be beneficial to identify patients
with otherwise negative antibodies.
Proper management of DM, including the use of intra-
venous corticosteroids, is essential to enable early cancer
treatment. Maintenance corticosteroid therapy does not
interfere with chemotherapy administration and can
provide control of the rheumatic disease during cancer
treatment.
Furthermore, we propose that anti-TIF-1γ antibodies
might serve as a prognostic marker of worse clinical out-
come in early breast cancer provided correlation between
serum anti-TIF-1γ antibodies and TIF-1γ expression in
the tumor is found.
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